Milczek Tomasz, Klasa-Mazurkiewicz Dagmara, Wydra Dariusz
Department of Gynecology, Gynecological Oncology and Gynecological Endocrinology, Medical University of Gdańsk, Gdańsk, Poland.
Department of Gynecology, Gynecological Oncology and Gynecological Endocrinology, Medical University of Gdańsk, Gdańsk, Poland.
Adv Med Sci. 2015 Sep;60(2):216-9. doi: 10.1016/j.advms.2015.03.001. Epub 2015 Apr 1.
To determine the complication rate associated with using a single-lumen intravenous access port with a silicone catheter of 9-10Fr size in the intraperitoneal treatment, including hyperthermic intraperitoneal chemotherapy, in ovarian cancer.
PATIENTS/METHODS: We reviewed 27 patients who had subcutaneous venous access ports placed for the administration of IP chemotherapy. With four patients, the catheter was implanted during a hyperthermic intraperitoneal chemotherapy-related laparotomy using the closed technique. Each case was categorized as to the number of cycles of IP therapy received.
Seven catheter-related complications were noted. These were divided into two categories: six malfunctions (24%) and one infection (4%). Overall, of the patients who had IP catheters placed and received IP chemotherapy, 13 (54.2%) were able to complete the six regimens. Among the four (14.8%) patients who had the catheters planted directly following the HIPEC, one experienced a catheter leak, one an infection and one concluded the treatment successfully; one is still being treated.
A subcutaneous single-lumen intravenous access port with a silicone catheter of a large size (9-10Fr) is related to a lower rate of catheter-related complications than previously reported open-ended Tenckhoff catheter treatment. An additional advantage is the possibility of removing the catheter as an office procedure under local anesthesia. Intraperitoneal chemotherapy following a HIPEC procedure may cause increased occurrence of catheter-related complications. As of 2010 we have been using silicone subcutaneous catheters in our center.
确定在卵巢癌腹腔内治疗（包括热灌注腹腔化疗）中使用9 - 10Fr尺寸硅胶导管的单腔静脉输液港的并发症发生率。
患者/方法：我们回顾了27例为接受腹腔内化疗而置入皮下静脉输液港的患者。其中4例患者在热灌注腹腔化疗相关的剖腹手术中采用封闭技术植入导管。每例患者根据接受的腹腔内治疗周期数进行分类。
共记录到7例与导管相关的并发症。这些并发症分为两类：6例故障（24%）和1例感染（4%）。总体而言，在置入腹腔内导管并接受腹腔内化疗的患者中，13例（54.2%）能够完成六个疗程。在热灌注腹腔化疗后直接植入导管的4例患者（14.8%）中，1例出现导管渗漏，1例发生感染，1例成功完成治疗；1例仍在接受治疗。
与先前报道的开放式Tenckhoff导管治疗相比，使用大尺寸（9 - 10Fr）硅胶导管的皮下单腔静脉输液港与导管相关并发症的发生率较低。另一个优点是可以在局部麻醉下作为门诊手术取出导管。热灌注腹腔化疗术后进行腹腔内化疗可能会导致导管相关并发症的发生率增加。自2010年起，我们中心一直在使用硅胶皮下导管。
